# A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

> **NCT06769048** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 150 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** Placebo-matching BI 1584862
- **DRUG:** BI 1584862

## Key facts

- **NCT ID:** NCT06769048
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2027-02-15
- **Final completion:** 2027-02-26
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769048, "A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06769048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*